ERBB2 and breast cancer: Results of a single large neoadjuvant trial NeoSPHERE demonstrated that pertuzumab added to trastuzumab plus docetaxel significantly increased pathologic complete response (pCR) in HER-2-positive EBC and locally advanced BC (LABC) [31].